Quentin M. Anstee

Framlington Place
Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 282 publications

Letter: Non-Invasive Tests After Semaglutide in MASH as Disease-Activity Readouts Rather Than Response Biomarkers. Authors' Reply.

Letter: Non-Invasive Tests After Semaglutide in MASH as Disease-Activity Readouts Rather Than Response Biomarkers. Authors' Reply.

Journal: Alimentary pharmacology & therapeutics

Published: July 22, 2026

Erratum: Noninvasive assessment of liver disease severity in NAFLD and T2D.

Erratum: Noninvasive assessment of liver disease severity in NAFLD and T2D.

Journal: Hepatology (Baltimore, Md.)

Published: July 17, 2026

Erratum to 'Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis' [J Hepatol 83 (2025) 239-257].

Erratum to 'Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis' [J Hepatol 83 (2025) 239-257].

Journal: Journal of hepatology

Published: April 28, 2026

EASL position paper on preclinical models of steatotic liver disease.

EASL position paper on preclinical models of steatotic liver disease.

Journal: Journal of hepatology

Published: April 28, 2026

Medical therapy of MASLD - consequences of the paradigm shift from histology to non-invasive tests.

Medical therapy of MASLD - consequences of the paradigm shift from histology to non-invasive tests.

Journal: JHEP reports : innovation in hepatology

Published: February 23, 2026

A data-driven framework reconstructs the molecular continuum of human MASLD progression.

A data-driven framework reconstructs the molecular continuum of human MASLD progression.

Journal: Nature metabolism

Published: January 27, 2026

Current therapeutic landscape and future treatment perspectives of MASH.

Current therapeutic landscape and future treatment perspectives of MASH.

Journal: Nature

Published: January 11, 2026

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.

Journal: The lancet. Gastroenterology & hepatology

Published: December 21, 2025

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.

Journal: Hepatology (Baltimore, Md.)

Published: December 17, 2025

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.

Journal: Hepatology (Baltimore, Md.)

Published: December 17, 2025

Reproducibility of Biomarkers in MASLD: A Benchmark for Clinically Meaningful Change in Serially Measured Non-Invasive Tests.

Reproducibility of Biomarkers in MASLD: A Benchmark for Clinically Meaningful Change in Serially Measured Non-Invasive Tests.

Journal: Journal of hepatology

Published: December 17, 2025

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.

Journal: Nature medicine

Published: December 11, 2025

Showing 1-12 of 282

Last Updated: 09/26/2026